Abstract
Mesenchymal stem or stromal cells (MSCs) have a high potential for cell-based therapies as well as for tissue engineering applications. Since Friedenstein first isolated stem or precursor cells from the human bone marrow (BM) stroma that were capable of osteogenesis, BM is currently the most common source for MSCs. However, BM presents several disadvantages, namely low frequency of MSCs, high donor-dependent variations in quality, and painful invasive intervention. Thus, tremendous research efforts have been observed during recent years to find alternative sources for MSCs.
In this context, the human umbilical cord (UC) has gained more and more attention. Since the UC is discarded after birth, the cells are easily accessible without ethical concerns. This postnatal organ was found to be rich in primitive stromal cells showing typical characteristics of bone-marrow MSCs (BMSCs), e.g., they grow as plastic-adherent cells with a fibroblastic morphology, express a set of typical surface markers, and can be directly differentiated at least along mesodermal lineages. Compared to BM, the UC tissue bears a higher frequency of stromal cells with a higher in vitro expansion potential. Furthermore, immune-privileged and immune-modulatory properties are reported for UC-derived cells, which open highly interesting perspectives for clinical applications.
Authors contributed equally to this work
1 Introduction
The engineering of stem cells to restore defect functions in human tissues is an exciting challenge in the field of regenerative medicine. Embryonic stem cells (ESC) have a great potential for this purpose due to their pluripotent differentiation capability, but their use is limited by serious ethical considerations. Recent findings evidencing the reprogramming of somatic cells to pluripotent stem cells (termed IPS cells) [1] open ethically acceptable perspectives. However the concern remains that undifferentiated IPS cells as well as ESC may form teratomas after transplantation in the body.
Adult mesenchymal stem or stromal cells (MSCs) are considered a valuable alternative to these cells. Since their discovery in bone marrow (BM) by Friedenstein et al. [2], BMSCs have been extensively investigated and their use in animal studies as well as in clinical trials showed encouraging results (reviewed in [3]). Today BM-MSCs are still considered as the “gold standard” for the use of adult MSCs. Nevertheless BM as a source for MSCs presents several disadvantages. Besides the invasive and painful collecting procedure, in BM-aspirates MSCs are present at very low frequency (approximately 0.001–0.01% [4]) and their quality varies with the age of the donor. The low frequency implies that an extensive in vitro expansion of the cells will be required to deliver clinical doses to a patient, which enhances the risk of epigenetic damages as well as viral and bacterial contaminations. For these reasons, alternative sources of MSCs are needed.
In this context, the human umbilical cord (UC) gained more and more attention during the last decade (see Fig. 1). The UC is a non-controversial and accessible source of autologous cells, which can be easily processed after birth. It has been demonstrated that MSCs are found both in the blood (UCB) [5] and in the tissues of UC. However, UCB-derived MSCs may have a limited technological potential because their frequency seems even lower than in BM (range 0.001–0.000001% [6]) and their isolation is hardly reproducible [7, 8], whereby UCB contains larger amounts of other tissue stem cell populations including CD133+ cells or hematopoietic stem cells (CD34+). In contrast, the frequency of MSCs in UC-tissues is believed to be much higher. Thus, using robust isolation procedures, a large number of multipotent primitive stromal cells with high proliferation capacity can be isolated. All these features open interesting perspectives for the scalable production and engineering of UC-derived cells for clinical applications. Here, we give an overview of the scientific evidences collected during the recent years that human UC may be a valuable cell source for cell-based therapies.
2 The Human Umbilical Cord: A Source of MSCs
The human UC is the lifeline between the fetus and the placenta. It is formed during the fifth week of embryogenesis and grows to a final length of approximately 60–65 cm, weighs about 40 g, and has a mean diameter of 1.5 cm in normal pregnancies [9, 10]. UC usually comprises two arteries and a vein, which are immersed within the so-called Wharton’s jelly (WJ) and enclosed by a simple amniotic epithelium (see Fig. 2a). WJ is a mucoid connective tissue rich in proteoglycans and hyaluronic acid (HA), which insulates and protects umbilical vessels from torsion, compression, or bending and therefore ensures a constant blood flow between fetus and placenta.
In recent years, several studies described at least four separate regions (see Fig. 2b) of the UC containing MSCs. The term “MSC” has been related to several definitions. In this chapter we use “MSC” as an acronym for mesenchymal stromal cell (discussed in Sect. 4). MSCs could successfully be isolated from UCB [7, 11–15], the umbilical vein subendothelium [16–18], the intervascular region [19–29], the perivascular region [30, 31], or from whole UC tissue [32, 33]. UC-derived MSCs meet the basic definition of multipotent MSCs as postulated by the International Society for Cellular Therapy (ISCT) (see Sect. 4).
Thus, this chapter will focus on MSCs derived from UC tissue, but not from UCB (see Fig. 2b, region 2–4).
3 Isolation of MSCs from the Umbilical Cord
In recent years, several investigators published protocols for isolating MSCs from the UC tissue. Depending on from which part of the cord the cells should be isolated, protocols have been adopted and modified. A schematic overview of applied isolation protocols is given in Fig. 3. Basically, the isolation procedure starts with the removal of umbilical vessels. The cord is then cut down to smaller segments or chopped into small pieces which are subsequently enzymatically digested [22, 23, 29]. Alternative isolation methods without removal of vessels [34, 35] and without enzymatic digestions [26, 34] or explant cultures [33, 36] have also been described. To isolate cells from the perivascular tissue or the subendothelium of the umbilical vein, further methods have been established [16–18, 30, 31].
We have used a protocol without enzymatic digestion and without removal of umbilical vessels to isolate MSC-like cells from whole UC tissue in an explant culture approach. Therefore, human UCs were obtained from patients with written consent delivering full-term (38–40 weeks) infants by cesarean section. The use of this material has been approved by the Institutional Review Board, project #3037 in an extended permission on June 17, 2006.
First, blood from arteries and the vein was removed by flushing phosphate buffered saline (PBS) through the vessels using a sterile syringe and blunt needles. Thereafter, UC was stored in an appropriate transfer medium (PBS) enriched with 5 g L−1 glucose, 50 μg mL−1 gentamicin, 2.5 μg mL−1 amphotericin B, 100 U.mL−1 penicillin, and 100 μg mL−1 streptomycin), to minimize the risk of contaminations. The UC was first cut into 10–15 cm long segments which were subsequently cut into approximately 0.5 cm3 large pieces. During the isolation procedure, transfer medium was used to keep the cord and the minced pieces moist. Finally, the small pieces were transferred to cell culture flaks (Fig. 4a) and incubated in αMEM supplemented with 15% of allogous human serum and 50 μg m−1 gentamicin at 37°C in a humidified atmosphere with 5% CO2. The medium was changed every second day. An outgrowth of adherent cells from single tissue pieces could be observed after approximately 10 days (Fig. 4b). After 2 weeks the UC tissue was removed and the adherent cells (Fig. 4c) were harvested by enzymatic treatment. The obtained cell suspension was centrifuged at 200 g for 5 min and the cells were resuspended in αMEM supplemented with 10% human serum and 50 μg mL−1 gentamicin and subcultured at a density of 4000 cells cm−2. These culture conditions have demonstrated to support an optimal growth of the cells.
The isolated cells exhibited a high proliferation potential. Cell population doubling times ranged from 27.5 ± 1.6 h (passage 2) to 78.9 ± 6.3 h (passage 17). At our culture conditions, the cells could be expanded without loss of proliferative activity and viability at least for 20 population doublings. After approximately 50 population doublings the cells entered a phase of replicative senescence. High proliferation potential and expansion capacity are common features for UC-derived stromal cells, which were described by several other groups [20, 26, 29, 30, 34, 35, 37, 38]. Furthermore, UC-derived cells could be efficiently cryopreserved and revitalized. We used a cryo-medium containing 80% human serum, 10% culture medium, and 10 % DMSO. The cells were gradually frozen at a rate of 1°C min−1 and finally stored at −196°C. At these conditions cell survival rate after rapid thawing at 37°C reached 75 ± 12.8%.
To date, it still remains to be further investigated whether cells isolated from different compartments or derived by different isolation procedures share the same stem cell characteristics, e.g., proliferation and differentiation potential and immunologic properties (see below).
4 Characterization of UC-Derived MSCs
The acronym “MSC” has been widely used in the literature for “mesenchymal stromal cell” as well as for “mesenchymal stem cell” to denominate plastic-adherent fibroblast-like cultures isolated from different adult or extra-embryonic tissues. Because there is currently no consensus set of markers allowing the identification of MSCs and considering the fact the definition criteria for stem cell is not unanimously accepted [39], it appeared unwise to apply the term “stem cell” for mesenchymal cell population. In this context, ISCT proposed to term plastic-adherent fibroblast cultures “multipotent mesenchymal stromal cells” (MSC) [40] and published in 2006 the minimal criteria defining these cells [41].
UC-derived stromal cells meet the basic criteria defined by the ISCT, namely the adherence to plastic, the expression of a set of specific surface antigens (see below), and a multipotent differentiation potential (discussed in paragraph 5 Differentiation Potential).
Histologically, cells freshly isolated from the UC are mainly fibroblastic in appearance (see Fig. 5a). However, some groups reported more than one phenotype in UC-derived MSC cultures [23, 29, 31, 36] and noticed changes in the distribution of the phenotype after several passages [23, 36]. Our group observed for instance a broad cell size distribution and marked morphological differences in isolated UC-MSCs cultures (see Fig. 5b). After fractionation of different populations via counterflow centrifugal elutriation (CCE) according to the size of the cells, we obtained two sub-populations with significant differences in cell size, growth properties, and biochemical markers expression. Whereas small-sized subpopulation exhibited the highest proliferative capacity and the most pronounced expression of MSC markers, large-sized cells were identified as senescent via β-galactosidase staining (see Fig. 6) [36]. These findings may be of importance in order to deliver high quality cells for clinical applications.
An additional feature of MSCs is their clonogenicity. A single cell is able to rise to a fibroblastic colony in a so-called colony forming unit fibroblast (CFU-F) assay. Historically, this characterization parameter is linked to the pioneer work of Friedenstein et al., who first isolated stromal cells from BM according to their capability to form fibroblastic colonies and demonstrated their osteogenic potential in vitro [2]. The CFU-F assay gives the frequency of fibroblast-like cells within a population liable to extensive proliferation and to rise to a colony (see Fig. 7).
This approach is commonly used to enumerate MSCs in a particular tissue [4]. For instance, Lu et al. recently evaluated the frequency at 1 CFU-F per 1609 mononuclear cells (MNCs) in whole UC tissues [35]. More specifically, 1 CFU-F per 333 MNCs was reported in cells isolated from perivascular tissues of the UC vein [31]. In comparison, the isolation frequency of CFU-F from BM is estimated in a range of 1–10 CFU-F per 105 MNCs [4] and only 1 CFU-F per 108 MNCs [7] to 1–3 CFU-F per 106 MNCs are reported in UCB [42, 43]. According to these data, the human UC is considered to harbor a higher number of MSCs than found in BM or UCB. The results of the CFU-F assay, however, depend on different parameter such as the isolation method, culture conditions, as well as the cell seeding density. This leads to a high degree of variability in the results and makes the comparison of the published data difficult. Analysis of specific molecule expression at the single cell level via flow cytometry is strongly advisable to identify MSCs within a mixed cell population.
In contrast to other progenitor cell populations, such as, for instance, hematopoeitic stem cells, there is currently no specific marker available defining human MSCs. The expression of a set of markers combined with the demonstration of in vitro multi-lineage differentiation potential is necessary to identify MSCs in UC-derived cell populations. Table 1 summarizes extracellular and intracellular molecules expressed by UC-MSCs reported in the literature up to July 2009.
The surface antigen SH2 (CD105), SH3 (CD73), and Thy-1 (CD90) are widely used for the identification of UC-derived stromal cells (see Table 1), as these markers are proposed by the ISCT as positive markers for human MSCs [41]. However, these epitopes are also expressed on hematopoietic and endothelial cells, which are two potential contaminants in UC-derived cell populations. Consequently, it is necessary to carefully exclude cells from hematopoietic or endothelial origin using surface marker such as CD45, CD34, or CD31. HA receptor CD44 is also a commonly accepted marker, as the extracellular matrix of the UC is one of the highest HA-containing tissue in humans [44]. Figure 8 exemplarily illustrates the immunophenotype of a stromal cell population isolated from whole UC tissue by our group. Additionally, like MSCs isolated from other tissues, UC-derived stroma cells do not express the human leukocyte antigen HLA-DR but express HLA-I. However, Sarugaser et al. reported that the expression of the latter marker may be manipulated in vitro, which may be very promising in term of allogenic transplantations [31].
UC-derived stroma cells were found positive for pluripotency markers usually expressed by ESCs such as Oct-3/4, Nanog, Sox-2, or SSEA-4 (see Table 1), which underlines their primitive nature. The primitive character of the UC-derived cells is also illustrated by their high proliferation and expansion capacity. UC-derived stroma cells have shorter doubling times compared to adult BM-MSCs [30, 35, 37, 38], exhibit telomerase activity [23, 26, 45], and could be expanded in vitro to a number of population doublings ranging from 20 to 80 without evidences of senescence or abnormal karyotype [20, 26, 29, 34]. It was first unclear whether UC-derived stroma cells were homogenous regarding their primitiveness or if UC-derived stroma populations rather harbor a subset of primitive MSCs [46]. For instance, population doubling times estimated between 60 and 85 h for freshly isolated UC-cells rapidly decrease within 2–3 passages to approximately 25 h [23, 31], which may indicate the presence of a fast growing sub-population of more primitive cells overgrowing the initial population. This hypothesis was further strengthened by recent works demonstrating via flow cytometry a subset of cells expressing pluripotency markers [47, 48]. Zhang et al., for instance, reported that approximately 20% of stroma cells isolated from perivascular tissues of the umbilical arteria express Oct-3/4 and Nanog [48].
With growing evidence that MSC-like cell population isolated from UC tissues are rather heterogeneous, at least in regard to primitive marker expression, the identification of a universal marker defining primitive human MSCs remains challenging. Several cell surface molecules were recently proposed for the identification and isolation of MSCs in BM aspirates such as CD271 [49, 50], MSCA-1 [50], SSEA-4 [51], and the neural ganglioside GD2 [52, 53]. To our knowledge, CD271 and MSCA-1 expressions have not been reported yet in UC-derived stroma cell populations. Xu et al. recently isolated a subset of GD2+ cells exhibiting a high clonogenicity as well as proliferation capacity but also a significantly stronger multi-differentiation potential than GD2− cells. According to these results, GD2 may be a useful marker to isolate multipotent MSCs from UC-tissues, but further studies are needed to verify these findings.
The most convincing biological property for the identification of MSCs remains the capability to differentiate into mesodermal lineages. In the next section the in vitro differentiation potential of UC-derived stromal cells will be discussed.
5 In Vitro Differentiation Potential
The differentiation repertoire of stroma cells derived from UC tissue reported in the literature till July 2009 is summarized in Table 2.
The potential of UC stroma cells to differentiate into adipocytes, chondrocytes, and osteocytes has been widely investigated and well established by several groups. According to the minimal definition criteria proposed by the ISCT, UC-derived stroma cells are considered multipotent MSCs [41]. Successful adipogenic, chondrogenic, and osteogenic differentiation of UC-derived MSCs are presented in Fig. 9.
Adipogenic potential is usually demonstrated by the apparition of cells exhibiting intracellular lipid droplets (Fig. 9a). The capacity to form chondroblasts is evidenced by the formation of shiny cell-spheres with type II collagen expression in the extracellular matrix in droplet cultures (Fig. 9b). Enhanced ALP expression and mineralization assayed by von Kossa or alizarin red staining demonstrate osteogenic potency (Fig. 9d, e). It should also be mentioned that sub-populations of cells spontaneously exhibiting a functional osteogenic potential with mineralized bone nodules can be observed in UC-MSCs cultures [31]. Such bone nodules are presented exemplary in Fig. 10.
In addition, it has been shown that UC-MSCs can successfully differentiate to endothelial cells after addition of VEGF and b-FGF [54, 55] and can form vessel-like structures in matrigel cultures [37, 55]. Furthermore, some UC-derived cell populations also seem to be able to differentiate to muscle cells. For instance, WJ cells (WJCs) could be induced to skeletal myocytes when placed in myogenic medium [20]. Differentiation to cardiomyocytes was also reported but remains controversial. Whang et al. demonstrated for instance that WJCs could be induced to cells exhibiting cardiomyocyte morphology and expressing specific markers (N-cadherin and cardiac troponin) using 5-azacytidine or cardiomyocyte-conditioned medium [28]. Kadivar et al. observed cardiomyocyte like cells expressing cardiac specific genes after 5-azacytidine induction of UC-MSCs isolated from the endothelium/subendothelium layer of the UC vein. In contrast to these results, Martin-Rendon et al. could not detect cardiac markers expression after in vitro induction of MSCs isolated from the WJs and perivascular tissues [56]. Furthermore, differentiated in vitro cultures of functional cardiomyocytes presenting beating clusters are poorly or not demonstrated. To our knowledge, only one group reported differentiated cells exhibiting slight spontaneous beating after 21 days of induction; however no quantitative data are presented in this study [57].
Recent findings suggest that UC-MSCs can differentiate into endodermal lineages. Campard et al. reported that UC-matrix cells constitutively expressed markers of hepatic lineage, such as albumin, alpha-fetoprotein, cytokeratin-19, connexin-32, and dipeptidyl peptidase IV. After in vitro hepatic induction, cells exhibiting a hepatocyte-like morphology with hepatic features such as specific markers up-regulation and urea production were observed. However, the authors pointed out that their cells lack important characteristics of functional liver cells and thus conclude that UC-matrix cells can be differentiated at least to immature hepatocytes [58]. Chao et al. were also able to induce WJCs using a four stage differentiation protocol to form islet-like clusters expressing pancreatic related genes and secreting insulin in response to glucose concentrations [59]. Recent results from Wu et al., who successfully differentiated WJCs to pancreatic cells and observed higher differentiation potential compared to BM-MSCs [38], further reinforce these findings.
Finally, several groups observed the differentiation of WJCs to cells exhibiting morphological and biochemical characteristics of neural cells, suggesting that UC-MSCs are able to differentiate to a certain state of maturation along the neuronal lineage [21–23, 25, 26, 35, 60–62]. Mitchell et al. were the first to observe neuronal differentiation of WJCs after stimulation with b-FGF and other neuronal differentiation reagents [26]. The differentiation was attested according to morphological changes and expression of neuron-specific enolase, βIII-tubulin, neurofilament M and tyrosin hydroxylase [26]. The differentiation potential was then confirmed by several other groups [21, 23, 25, 60]. Figure 11 shows exemplary neuronal cells obtained by Karahuseyinoglu et al. after neuronal induction of a sub-population of WJCs [23]. Interestingly, it also seems possible to generate some sub-types of neurones as demonstrated by Fu et al., who were able to obtain dopaminergic neurones from WJCs [21].
Summarizing the published data, we find strong evidence to suggest that the human UC is a source of multipotent stroma cells which are capable of differentiating into mesodermal and non-mesodermal lineages. It remains unclear whether the differentiation potential of the UC-derived MSCs depends on their location in the UC-tissues. For instance, Suzdal'tseva et al. reported that only a few cells isolated from the cord vein subendothelial tissue were able to differentiate to osteoblasts [63]. In contrast, cells isolated from perivascular tissues of the umbilical vein showed a high osteogenic potential with spontaneous formation of bone nodules [31], which was even evaluated higher than the potential of bone-marrow MSCs in a comparative study [30]. Recently, two sub-populations were evidenced in cultures of WJ-derived MSCs with regard to the expression of vimentin and pan-cytokeratin filaments [23]. Interestingly, cells expressing cytokeratin, predominantly located in the perivascular tissue of the cord, did not differentiate into neurones in vitro. These findings are consistent with the results of Sarugaser et al., who showed that perivascular UC-cells could not be induced to the neuronal lineage [31]. The hypothesis of a location-dependent differentiation potential of UC-derived stroma cells is also supported by the fact that a gradient of cell maturity was observed within the UC tissues [64]. According to the cytoskeletal complexity, the most immature cells are located in subamniotic and intervascular regions, whereas cells of perivascular regions may represent a more differentiated state [64, 65].
Many groups most likely investigate mixed populations of UC-MSCs, particularly if the cells are derived from whole UC or from the WJ. Thus, the results of studies comparing the differentiation potential of UC-derived MSCs with other sources (for example BM) should be carefully interpreted [17, 56, 66, 67]. More work is needed to attest whether cells isolated from a defined compartment of the UC is more suitable for a specific differentiation lineage. This information would be of tremendous importance for clinical applications of UC-derived MSCs.
6 Immune Properties of MSCs and In Vivo Applications
Besides their multi-lineage differentiation potential, BM-derived MSCs have been shown to exhibit immune-privileged and immune-modulatory properties, which predestine them as ideal candidates for cell-based therapies. They fail to induce proliferation of allogeneic lymphocytes in vitro and do not induce an immune response when used in allogenic mismatched animal experimental models [68–70]. Furthermore, they have regulatory effects on several cells of the immune system (e.g., T, B, dendritic, and natural killer cells) [71–77], prolong skin graft survival [78], and have been used in clinical applications to reduce acute and chronic graft-versus-host disease (GvHD) [79, 80]. Currently, three groups have investigated the in vitro immune properties of UC-derived MSCs and observed similar immunologic phenotypes to that of BM-MSCs. Ennis et al. [81] used cells isolated from the perivascular tissue of the UC [human UC perivascular cells (HUCPVC)] in one- and two-way mixed lymphocyte cultures (MLC) with resting or activated peripheral blood lymphocytes (PBL) to examine whether HUCPVCs induce or modulate proliferation of immune cells. Proliferation of PBLs was determined by measurement of 5-bromo-2-deoxyuridine (BrdU) or tritiated thymidine [3H] incorporation. They could show that HUCPVCs did not induce allogenic lymphocyte proliferation but reduced the proliferation of alloreactive PBLs in a dose-dependent way. Weiss et al. [82] describe similar observations using WJ-derived cells termed UC matrix stroma (UCMS) cells. In co-culture experiments they could show that UCMS cells not only suppressed the proliferation of Con-A-stimulated rat splenocytes [measured by live cell counting, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-assay and carboxyfluorescein diacetate succinimidyl ester (CFSE)-assay] and activated human peripheral blood mononuclear cells (PBMCs) or purified T cells (measured by tritiated thymidine [3H] incorporation) but also did not induce any proliferation of resting immune cells. Furthermore, flow cytometric analysis revealed the absence of the immune response-related surface antigens CD40, CD80, and CD86. Yoo et al. [83] compared the immune-suppressive effect of BM-MSCs and WJ-derived MSCs on phytohemagglutinin-induced T cell proliferation and report that both BM-MSCs and WJ-MSCs effectively reduced the proliferation of immune cells.
In vivo applications of UC-MSCs revealed further interesting attributes similar to BM-MSCs. Regarding their potential for cell-based therapy applications, UC-derived mesenchymal cells seem to support tissue repair by stimulating and modulating tissue-specific cells rather than differentiating into specialized cells. Yang et al. [84] reported a positive modulation of microglia and reactive astrocytes activities by UC-MSCs when transplanted into rats after complete transection of the spinal cord. They detected an elevated production of various cytokines around the lesion promoting spinal cord repair. Similar to these findings, Weiss et al. [29] hypothesized a supportive function of UC-MSCs mediated by various secreted trophic factors when used in a rodent model of Parkinson’s disease. Referring to their preliminary work on porcine UC-derived MSCs, which were successfully transplanted into rat brains without triggering an immune response or being rejected [85], they then transplanted human UC-MSCs into brains of Parkinson’s disease model rats without any immune-suppression. The transplanted cells did not produce brain tumors or a frank host immune rejection response. Furthermore, they significantly mitigated induced motor deficits [29]. Liao et al. [86] used UC-derived MSCs in a rodent stroke model and observed that the cells, injected into the rat brain, survived for at least 5 weeks and reduced injury volume and neurologic functional deficits of rats after stroke. They assume angiogenesis-promoting properties of the cells by producing angiogenic cytokines. Koh et al. [87] also applied a rodent stroke model. They used MSCs isolated from the umbilical vein sub-endothelium and induced differentiation of the cells into neuron-like cells, as indicated by morphology, expression of neuronal cell markers, and secretion of neurotrophic factors, before transplantation into rats. Since the UC-MSCs were both morphologically differentiated into neuronal cells and able to produce neurotrophic factors, but had not become functionally active neuronal cells, the authors hypothesize that the observed improvement in neurobehavioral function might be related to the neuroprotective effects of UC-MSCs rather than to the formation of a new network between host neurons and the implanted cells. Analogical findings were reported by Lund et al. [24]. They suggested a supportive behavior of MSCs in a rodent model of retinal disease when UC-MSCs were shown to contribute to photoreceptor rescue. The cells did not transform into neurons but more likely secreted neurotrophic factors, as indicated by higher expression levels of these factors in vitro.
Besides their supporting properties, UC-MSCs were also shown to be easily genetically manipulated. Friedman et al. [88] and Kermani et al. [89] both transfected UC-tissue derived MSCs with a GFP-reporter gene and created a stable cell line. Considering the immune-privileged and immune-modulatory properties, the cytokine production and supportive functions in vivo and the ability to be easily transfected, UC-derived mesenchymal cells are promising candidates for cell-based therapies and clinical applications. Currently, there are first clinical trials aiming to demonstrate if human UC-MSC have in vivo immune-suppressive effects and can be used for GVHD treatment [“Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment (MSCGVHD)”; ClinicalTrials.gov Identifier: NCT00749164; www.ClinicalTrials.gov].
7 Future Perspectives
In terms of cell engineering, the human UC is a very advantageous source of MSCs. Cells from UC are easily accessible, may be processed under GMP conditions, and the isolation of a high number of MSCs can be rapidly achieved in a reproducible manner. Particularly interesting features of UC-MSCs were evidenced in recent years. Due to their youth, UC-derived MSCs exhibit a high proliferation capacity and expansion potential. Thus, compared to other MSC-sources, for UC-derived MSCs no extensive expansion is required to obtain clinical doses, thereby reducing the risk of possible epigenetic damages occurring during the in vitro expansion process. Because one of the challenges of the bioprocesses will be the generation of clinical grade MSCs in disposable reactors, the monitoring of the cultures will be essential to control cell quality. The development of adequate in situ sensors for the monitoring of the cultures will be of great interest [90]. Furthermore, it has been shown that UC-MSCs can be frozen and thawed efficiently, which makes them suitable for their use in clinical cell banking. The therapeutic use of MSCs will require storage prior to clinical applications. In this regard, it appears worthwhile that UC-cells isolated at birth, may be safely stored and delivered decades later to a patient. Nevertheless, additional studies may be necessary to attest the stability of long term cryopreserved cells.
The clinical potential of MSCs is primary dependent on their differentiation potential. Like BM stromal cells, UC-derived MSCs were demonstrated to be multipotent. Interestingly, their differentiation repertoire does not seem to be restricted to the mesodermal lineages, since the cells could be successfully induced to neurones, liver, and pancreatic cells. A growing body of evidences suggests, however, that UC-MSC populations are rather heterogeneous, harboring a subset of primitive cells. The next generation of studies should focus on the identification and characterization of these sub-populations. In particular, the question of whether the differentiation potential of the isolated populations is dependent on their location in the UC-tissues is of great interest for clinical application. Newly described MSCs markers may be helpful in this regard.
Additionally, first in vitro and in vivo animal studies evidenced immune-privileged and immune-modulatory properties of UC-derived MSCs. Low levels of rejection were observed in all reports of in vivo transplantation experiments and encouraging results in tissue repairs were observed. In particular, supportive function through paracrine effects seems to be involved. The next generation of studies and first clinical trials will clarify whether the benefit of UC-derived MSCs after transplantation experiments relies on supportive effects and/or on differentiation in vivo.
One of the ambitious aims of regenerative medicine is the engineering of tissue in vitro. Few but very promising applications of UC-derived MSCs have been reported in this field. For instance, UC-MSCs are believed to have a high potential in cardiovascular tissue engineering [91]. They grew very well on bio-degradable polymer for the elaboration of cardiovascular constructs [33] and could be used for the construction of human pulmonary conduits [92], for the engineering of biologically active living heart valve leaflets [27], and for the elaboration of living patches with potential for pediatric cardiovascular tissue engineering [93]. The use of newly developed scaffolds, mechanical strain approaches, or 3D bioreactors for tissue generation, which were successfully applied with MSCs from other sources [94], will also be a highly interesting issue.
Considering the very encouraging results obtained in recent years, it may only be a question of time until UC-derived MSCs will be routinely used for clinical and tissue engineering applications.
Abbreviations
- ALP:
-
Alkaline phosphatase
- b-FGF:
-
Basic fibroblast growth factor
- BM:
-
Bone marrow
- BrdU:
-
5-Bromo-2-deoxyuridine
- CCE:
-
Counterflow centrifugal elutriation
- CD:
-
Cluster of differentiation
- CFSE:
-
Carboxyfluorescein diacetate succinimidyl ester
- CFU-F:
-
Colony forming unit-fibroblast
- DAPI:
-
4′,6-Diamidino-2-phenylindole
- ESC:
-
Embryonic stem cell
- GMP:
-
Good manufacturing practice
- GvHD:
-
Graft-versus-host disease
- HA:
-
Hyaluronic acid
- HLA:
-
Human leukozyte antigen
- HUCPVC:
-
Human umbilical cord perivascular cells
- ISCT:
-
International Society for Cellular Therapy
- MLC:
-
Mixed lymphocyte culture
- MSC:
-
Mesenchymal stromal cell
- MTT:
-
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- PBL:
-
Peripheral blood lymphocytes
- PBMC:
-
Peripheral blood mononuclear cell
- PBS:
-
Phosphate buffered saline
- UC:
-
Umbilical cord
- UCB:
-
Umbilical cord blood
- UCMS:
-
Umbilical cord matrix cells
- VEGF:
-
Vascular endothelial growth factor
- WJ:
-
Wharton’s jelly
- WJC:
-
Wharton’s jelly cell
References
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872
Friedenstein AJ, Chailakhjan RK, Lalykina KS (1970) The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 3:393–403
Bajada S, Mazakova I, Richardson JB, Ashammakhi N (2008) Updates on stem cells and their applications in regenerative medicine. J Tissue Eng Regen Med 2:169–183
Castro-Malaspina H, Gay RE, Resnick G, Kapoor N, Meyers P, Chiarieri D, McKenzie S, Broxmeyer HE, Moore MA (1980) Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 56:289–301
Kogler G, Sensken S, Airey JA, Trapp T, Muschen M, Feldhahn N, Liedtke S, Sorg RV, Fischer J, Rosenbaum C, Greschat S, Knipper A, Bender J, Degistirici O, Gao J, Caplan AI, Colletti EJ, Almeida-Porada G, Muller HW, Zanjani E, Wernet P (2004) A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 200:123–135
Sensebe L (2008) Clinical grade production of mesenchymal stem cells. Biomed Mater Eng 18:S3–S10
Bieback K, Kern S, Kluter H, Eichler H (2004) Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 22:625–634
Wexler SA, Donaldson C, Denning-Kendall P, Rice C, Bradley B, Hows JM (2003) Adult bone marrow is a rich source of human mesenchymal ‘stem’ cells but umbilical cord and mobilized adult blood are not. Br J Haematol 121:368–374
Di Naro E, Ghezzi F, Raio L, Franchi M, D'Addario V (2001) Umbilical cord morphology and pregnancy outcome. Eur J Obstet Gynecol Reprod Biol 96:150–157
Raio L, Ghezzi F, Di Naro E, Gomez R, Franchi M, Mazor M, Bruhwiler H (1999) Sonographic measurement of the umbilical cord and fetal anthropometric parameters. Eur J Obstet Gynecol Reprod Biol 83:131–135
Bieback K, Kluter H (2007) Mesenchymal stromal cells from umbilical cord blood. Curr Stem Cell Res Ther 2:310–323
Gang EJ, Jeong JA, Han S, Yan Q, Jeon CJ, Kim H (2006) In vitro endothelial potential of human UC blood-derived mesenchymal stem cells. Cytotherapy 8:215–227
Gang EJ, Jeong JA, Hong SH, Hwang SH, Kim SW, Yang IH, Ahn C, Han H, Kim H (2004) Skeletal myogenic differentiation of mesenchymal stem cells isolated from human umbilical cord blood. Stem Cells 22:617–624
Hou L, Cao H, Wang D, Wei G, Bai C, Zhang Y, Pei X (2003) Induction of umbilical cord blood mesenchymal stem cells into neuron-like cells in vitro. Int J Hematol 78:256–261
Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH (2004) Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 103:1669–1675
Covas DT, Siufi JL, Silva AR, Orellana MD (2003) Isolation and culture of umbilical vein mesenchymal stem cells. Braz J Med Biol Res 36:1179–1183
Panepucci RA, Siufi JL, Silva WA Jr, Proto-Siquiera R, Neder L, Orellana M, Rocha V, Covas DT, Zago MA (2004) Comparison of gene expression of umbilical cord vein and bone marrow-derived mesenchymal stem cells. Stem Cells 22:1263–1278
Romanov YA, Svintsitskaya VA, Smirnov VN (2003) Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells 21:105–110
Bailey MM, Wang L, Bode CJ, Mitchell KE, Detamore MS (2007) A comparison of human umbilical cord matrix stem cells and temporomandibular joint condylar chondrocytes for tissue engineering temporomandibular joint condylar cartilage. Tissue Eng 13:2003–2010
Conconi MT, Burra P, Di Liddo R, Calore C, Turetta M, Bellini S, Bo P, Nussdorfer GG, Parnigotto PP (2006) CD105(+) cells from Wharton's jelly show in vitro and in vivo myogenic differentiative potential. Int J Mol Med 18:1089–1096
Fu YS, Cheng YC, Lin MY, Cheng H, Chu PM, Chou SC, Shih YH, Ko MH, Sung MS (2006) Conversion of human umbilical cord mesenchymal stem cells in Wharton's jelly to dopaminergic neurons in vitro: potential therapeutic application for Parkinsonism. Stem Cells 24:115–124
Fu YS, Shih YT, Cheng YC, Min MY (2004) Transformation of human umbilical mesenchymal cells into neurons in vitro. J Biomed Sci 11:652–660
Karahuseyinoglu S, Cinar O, Kilic E, Kara F, Akay GG, Demiralp DO, Tukun A, Uckan D, Can A (2007) Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells 25:319–331
Lund RD, Wang S, Lu B, Girman S, Holmes T, Sauve Y, Messina DJ, Harris IR, Kihm AJ, Harmon AM, Chin FY, Gosiewska A, Mistry SK (2007) Cells isolated from umbilical cord tissue rescue photoreceptors and visual functions in a rodent model of retinal disease. Stem Cells 25:602–611
Ma L, Feng XY, Cui BL, Law F, Jiang XW, Yang LY, Xie QD, Huang TH (2005) Human umbilical cord Wharton's Jelly-derived mesenchymal stem cells differentiation into nerve-like cells. Chin Med J (Engl) 118:1987–1993
Mitchell KE, Weiss ML, Mitchell BM, Martin P, Davis D, Morales L, Helwig B, Beerenstrauch M, Abou-Easa K, Hildreth T, Troyer D, Medicetty S (2003) Matrix cells from Wharton's jelly form neurons and glia. Stem Cells 21:50–60
Schmidt D, Mol A, Odermatt B, Neuenschwander S, Breymann C, Gossi M, Genoni M, Zund G, Hoerstrup SP (2006) Engineering of biologically active living heart valve leaflets using human umbilical cord-derived progenitor cells. Tissue Eng 12:3223–3232
Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, Fu YS, Lai MC, Chen CC (2004) Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells 22:1330–1337
Weiss ML, Medicetty S, Bledsoe AR, Rachakatla RS, Choi M, Merchav S, Luo Y, Rao MS, Velagaleti G, Troyer D (2006) Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells 24:781–792
Baksh D, Yao R, Tuan RS (2007) Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 25:1384–1392
Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE (2005) Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells 23:220–229
Kadner A, Hoerstrup SP, Tracy J, Breymann C, Maurus CF, Melnitchouk S, Kadner G, Zund G, Turina M (2002) Human umbilical cord cells: a new cell source for cardiovascular tissue engineering. Ann Thorac Surg 74:S1422–S1428
Kadner A, Zund G, Maurus C, Breymann C, Yakarisik S, Kadner G, Turina M, Hoerstrup SP (2004) Human umbilical cord cells for cardiovascular tissue engineering: a comparative study. Eur J Cardiothorac Surg 25:635–641
La Rocca G, Anzalone R, Corrao S, Magno F, Loria T, Lo Iacono M, Di Stefano A, Giannuzzi P, Marasa L, Cappello F, Zummo G, Farina F (2009) Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers. Histochem Cell Biol 131:267–282
Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, Han ZB, Xu ZS, Lu YX, Liu D, Chen ZZ, Han ZC (2006) Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 91:1017–1026
Majore I, Moretti P, Hass R, Kasper C (2009) Identification of subpopulations in mesenchymal stem cell-like cultures from human umbilical cord. Cell Commun Signal 7:6
Chen MY, Lie PC, Li ZL, Wei X (2009) Endothelial differentiation of Wharton's jelly-derived mesenchymal stem cells in comparison with bone marrow-derived mesenchymal stem cells. Exp Hematol 37:629–640
Wu LF, Wang NN, Liu YS, Wei X (2009) Differentiation of Wharton’s jelly primitive stromal cells into insulin-producing cells in comparison with bone marrow mesenchymal stem cells. Tissue Eng Part A 15:2865–2873
Parker GC, Anastassova-Kristeva M, Eisenberg LM, Rao MS, Williams MA, Sanberg PR, English D (2005) Stem cells: shibboleths of development, part II: toward a functional definition. Stem Cells Dev 14:463–469
Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, Deans RJ, Krause DS, Keating A (2005) Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy 7:393–395
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315–317
Goodwin HS, Bicknese AR, Chien SN, Bogucki BD, Quinn CO, Wall DA (2001) Multilineage differentiation activity by cells isolated from umbilical cord blood: expression of bone, fat, and neural markers. Biol Blood Marrow Transplant 7:581–588
Wang JF, Wang LJ, Wu YF, Xiang Y, Xie CG, Jia BB, Harrington J, McNiece IK (2004) Mesenchymal stem/progenitor cells in human umbilical cord blood as support for ex vivo expansion of CD34(+) hematopoietic stem cells and for chondrogenic differentiation. Haematologica 89:837–844
Raio L, Cromi A, Ghezzi F, Passi A, Karousou E, Viola M, Vigetti D, De Luca G, Bolis P (2005) Hyaluronan content of Wharton's jelly in healthy and Down syndrome fetuses. Matrix Biol 24:166–174
Jo CH, Kim OS, Park EY, Kim BJ, Lee JH, Kang SB, Lee JH, Han HS, Rhee SH, Yoon KS (2008) Fetal mesenchymal stem cells derived from human umbilical cord sustain primitive characteristics during extensive expansion. Cell Tissue Res 334:423–433
Weiss ML, Troyer DL (2006) Stem cells in the umbilical cord. Stem Cell Rev 2:155–162
Xu J, Liao W, Gu D, Liang L, Liu M, Du W, Liu P, Zhang L, Lu S, Dong C, Zhou B, Han Z (2009) Neural ganglioside GD2 identifies a subpopulation of mesenchymal stem cells in umbilical cord. Cell Physiol Biochem 23:415–424
Zhang ZY, Teoh SH, Chong MS, Schantz JT, Fisk NM, Choolani MA, Chan J (2009) Superior osteogenic capacity for bone tissue engineering of fetal compared with perinatal and adult mesenchymal stem cells. Stem Cells 27:126–137
Buhring HJ, Battula VL, Treml S, Schewe B, Kanz L, Vogel W (2007) Novel markers for the prospective isolation of human MSC. Ann N Y Acad Sci 1106:262–271
Battula VL, Treml S, Bareiss PM, Gieseke F, Roelofs H, de Zwart P, Muller I, Schewe B, Skutella T, Fibbe WE, Kanz L, Buhring HJ (2009) Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica 94:173–184
Gang EJ, Bosnakovski D, Figueiredo CA, Visser JW, Perlingeiro RC (2007) SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood 109:1743–1751
Martinez C, Hofmann TJ, Marino R, Dominici M, Horwitz EM (2007) Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood 109:4245–4248
Karahuseyinoglu S, Kocaefe C, Balci D, Erdemli E, Can A (2008) Functional structure of adipocytes differentiated from human umbilical cord stroma-derived stem cells. Stem Cells 26:682–691
Wu KH, Zhou B, Lu SH, Feng B, Yang SG, Du WT, Gu DS, Han ZC, Liu YL (2007) In vitro and in vivo differentiation of human umbilical cord derived stem cells into endothelial cells. J Cell Biochem 100:608–616
Kestendjieva S, Kyurkchiev D, Tsvetkova G, Mehandjiev T, Dimitrov A, Nikolov A, Kyurkchiev S (2008) Characterization of mesenchymal stem cells isolated from the human umbilical cord. Cell Biol Int 32:724–732
Martin-Rendon E, Sweeney D, Lu F, Girdlestone J, Navarrete C, Watt SM (2008) 5-Azacytidine-treated human mesenchymal stem/progenitor cells derived from umbilical cord, cord blood and bone marrow do not generate cardiomyocytes in vitro at high frequencies. Vox Sang 95:137–148
Pereira WC, Khushnooma I, Madkaikar M, Ghosh K (2008) Reproducible methodology for the isolation of mesenchymal stem cells from human umbilical cord and its potential for cardiomyocyte generation. J Tissue Eng Regen Med 2:394–399
Campard D, Lysy PA, Najimi M, Sokal EM (2008) Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. Gastroenterology 134:833–848
Chao KC, Chao KF, Fu YS, Liu SH (2008) Islet-like clusters derived from mesenchymal stem cells in Wharton's Jelly of the human umbilical cord for transplantation to control type 1 diabetes. PLoS ONE 3:e1451
Kadam SS, Tiwari S, Bhonde RR (2009) Simultaneous isolation of vascular endothelial cells and mesenchymal stem cells from the human umbilical cord. In Vitro Cell Dev Biol Anim 45:23–27
Ma L, Cui BL, Feng XY, Law FD, Jiang XW, Yang LY, Xie QD, Huang TH (2006) Biological characteristics of human umbilical cord-derived mesenchymal stem cells and their differentiation into neurocyte-like cells. Zhonghua Er Ke Za Zhi 44:513–517
Chou SC, Ko TL, Fu YY, Wang HW, Fu YS (2008) Identification of genetic networks during mesenchymal stem cell transformation into neurons. Chin J Physiol 51:230–246
Suzdal'tseva YG, Burunova VV, Vakhrushev IV, Yarygin VN, Yarygin KN (2007) Capability of human mesenchymal cells isolated from different sources to differentiation into tissues of mesodermal origin. Bull Exp Biol Med 143:114–121
Nanaev AK, Kohnen G, Milovanov AP, Domogatsky SP, Kaufmann P (1997) Stromal differentiation and architecture of the human umbilical cord. Placenta 18:53–64
Kobayashi K, Kubota T, Aso T (1998) Study on myofibroblast differentiation in the stromal cells of Wharton’s jelly: expression and localization of alpha-smooth muscle actin. Early Hum Dev 51:223–233
Hou T, Xu J, Wu X, Xie Z, Luo F, Zhang Z, Zeng L (2009) Umbilical cord Wharton’s jelly: a new potential cell source of mesenchymal stromal cells for bone tissue engineering. Tissue Eng Part A
Sudo K, Kanno M, Miharada K, Ogawa S, Hiroyama T, Saijo K, Nakamura Y (2007) Mesenchymal progenitors able to differentiate into osteogenic, chondrogenic, and/or adipogenic cells in vitro are present in most primary fibroblast-like cell populations. Stem Cells 25:1610–1617
Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R (2003) Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 101:2999–3001
Kraitchman DL, Heldman AW, Atalar E, Amado LC, Martin BJ, Pittenger MF, Hare JM, Bulte JW (2003) In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation 107:2290–2293
Pochampally RR, Neville BT, Schwarz EJ, Li MM, Prockop DJ (2004) Rat adult stem cells (marrow stromal cells) engraft and differentiate in chick embryos without evidence of cell fusion. Proc Natl Acad Sci USA 101:9282–9285
Deans RJ, Moseley AB (2000) Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 28:875–884
Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838–3843
Le Blanc K (2003) Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 5:485–489
Le Blanc K, Ringden O (2005) Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11:321–334
Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O (2003) HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31:890–896
Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O (2003) Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57:11–20
Uccelli A, Moretta L, Pistoia V (2006) Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 36:2566–2573
Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30:42–48
Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439–1441
Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B, Aschan J, Barkholt L, Le Blanc K (2006) Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81:1390–1397
Ennis J, Gotherstrom C, Le Blanc K, Davies JE (2008) In vitro immunologic properties of human umbilical cord perivascular cells. Cytotherapy 10:174–181
Weiss ML, Anderson C, Medicetty S, Seshareddy KB, Weiss RJ, VanderWerff I, Troyer D, McIntosh KR (2008) Immune properties of human umbilical cord Wharton’s jelly-derived cells. Stem Cells 26:2865–2874
Yoo KH, Jang IK, Lee MW, Kim HE, Yang MS, Eom Y, Lee JE, Kim YJ, Yang SK, Jung HL, Sung KW, Kim CW, Koo HH (2009) Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol
Yang CC, Shih YH, Ko MH, Hsu SY, Cheng H, Fu YS (2008) Transplantation of human umbilical mesenchymal stem cells from Wharton’s jelly after complete transection of the rat spinal cord. PLoS ONE 3:e3336
Weiss ML, Mitchell KE, Hix JE, Medicetty S, El-Zarkouny SZ, Grieger D, Troyer DL (2003) Transplantation of porcine umbilical cord matrix cells into the rat brain. Exp Neurol 182:288–299
Liao W, Xie J, Zhong J, Liu Y, Du L, Zhou B, Xu J, Liu P, Yang S, Wang J, Han Z, Han ZC (2009) Therapeutic effect of human umbilical cord multipotent mesenchymal stromal cells in a rat model of stroke. Transplantation 87:350–359
Koh SH, Kim KS, Choi MR, Jung KH, Park KS, Chai YG, Roh W, Hwang SJ, Ko HJ, Huh YM, Kim HT, Kim SH (2008) Implantation of human umbilical cord-derived mesenchymal stem cells as a neuroprotective therapy for ischemic stroke in rats. Brain Res 1229:233–248
Friedman R, Betancur M, Boissel L, Tuncer H, Cetrulo C, Klingemann H (2007) Umbilical cord mesenchymal stem cells: adjuvants for human cell transplantation. Biol Blood Marrow Transplant 13:1477–1486
Kermani AJ, Fathi F, Mowla SJ (2008) Characterization and genetic manipulation of human umbilical cord vein mesenchymal stem cells: potential application in cell-based gene therapy. Rejuvenation Res 11:379–386
Glindkamp A, Riechers D, Rehbock C, Hitzmann B, Scheper T, Reardon KF (2009) Sensors in disposable bioreactors status and trends. Adv Biochem Eng Biotechnol
Breymann C, Schmidt D, Hoerstrup SP (2006) Umbilical cord cells as a source of cardiovascular tissue engineering. Stem Cell Rev 2:87–92
Hoerstrup SP, Kadner A, Breymann C, Maurus CF, Guenter CI, Sodian R, Visjager JF, Zund G, Turina MI (2002) Living, autologous pulmonary artery conduits tissue engineered from human umbilical cord cells. Ann Thorac Surg 74:46–52 discussion 52
Schmidt D, Mol A, Neuenschwander S, Breymann C, Gossi M, Zund G, Turina M, Hoerstrup SP (2005) Living patches engineered from human umbilical cord derived fibroblasts and endothelial progenitor cells. Eur J Cardiothorac Surg 27:795–800
van Griensven M, Diederichs S, Roeker S, Boehm S, Peterbauer A, Wolbank S, Riechers D, Stahl F, Kasper C (2009) Mechanical strain using 2D and 3D bioreactors induces osteogenesis: implications for bone tissue engineering. Adv Biochem Eng Biotechnol 112:95–123
Fan X, Liu T, Liu Y, Ma X, Cui Z (2009) Optimization of primary culture condition for mesenchymal stem cells derived from umbilical cord blood with factorial design. Biotechnol Prog 25:499–507
Lechner V, Hocht B, Ulrichs K, Thiede A, Meyer T (2007) Obtaining of mesenchymal progenitor cells from the human umbilical cord. Zentralbl Chir 132:358–364
Lupatov AY, Karalkin PA, Suzdal'tseva YG, Burunova VV, Yarygin VN, Yarygin KN (2006) Cytofluorometric analysis of phenotypes of human bone marrow and umbilical fibroblast-like cells. Bull Exp Biol Med 142:521–526
Walenda T, Bork S, Horn P, Wein F, Saffrich R, Diehlmann A, Eckstein V, Ho AD, Wagner W (2009) Co-culture with mesenchymal stromal cells increases proliferation and maintenance of hematopoietic progenitor cells. J Cell Mol Med
Yan Y, Xu W, Qian H, Si Y, Zhu W, Cao H, Zhou H, Mao F (2009) Mesenchymal stem cells from human umbilical cords ameliorate mouse hepatic injury in vivo. Liver Int 29:356–365
Yu Y, Ren H, Yun W, Jin Y, Li K, Du L (2008) Differentiation of human umbilical cord blood-derived mesenchymal stem cells into chondroblast and osteoblasts. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 25:1385–1389
Liu XD, Liu B, Li XS, Mao N (2007) Isolation and identification of mesenchymal stem cells from perfusion of human umbilical cord vein. Zhongguo Shi Yan Xue Ye Xue Za Zhi 15:1019–1022
Diao Y, Ma Q, Cui F, Zhong Y (2009) Human umbilical cord mesenchymal stem cells: osteogenesis in vivo as seed cells for bone tissue engineering. J Biomed Mater Res A 91(1):123–131
Bakhshi T, Zabriskie RC, Bodie S, Kidd S, Ramin S, Paganessi LA, Gregory SA, Fung HC, Christopherson KW 2nd (2008) Mesenchymal stem cells from the Wharton’s jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long-term ex vivo culture. Transfusion 48:2638–2644
Kadivar M, Khatami S, Mortazavi Y, Shokrgozar MA, Taghikhani M, Soleimani M (2006) In vitro cardiomyogenic potential of human umbilical vein-derived mesenchymal stem cells. Biochem Biophys Res Commun 340:639–647
Qiao C, Xu W, Zhu W, Hu J, Qian H, Yin Q, Jiang R, Yan Y, Mao F, Yang H, Wang X, Chen Y (2008) Human mesenchymal stem cells isolated from the umbilical cord. Cell Biol Int 32:8–15
Lu LL, Song YP, Wei XD, Fang BJ, Zhang YL, Li YF (2008) Comparative characterization of mesenchymal stem cells from human umbilical cord tissue and bone marrow. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16:140–146
Covas DT, Panepucci RA, Fontes AM, Silva WA Jr, Orellana MD, Freitas MC, Neder L, Santos AR, Peres LC, Jamur MC, Zago MA (2008) Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp Hematol 36:642–654
Magin AS, Koerfer NR, Partenheimer H, Lange C, Zander A, Noll T (2008) Primary cells as feeder cells for coculture expansion of human hematopoietic stem cells from umbilical cord blood a comparative study. Stem Cells Dev
Carlin R, Davis D, Weiss M, Schultz B, Troyer D (2006) Expression of early transcription factors Oct-4, Sox-2 and Nanog by porcine umbilical cord (PUC) matrix cells. Reprod Biol Endocrinol 4:8
Hiroyama T, Sudo K, Aoki N, Miharada K, Danjo I, Fujioka T, Nagasawa T, Nakamura Y (2008) Human umbilical cord-derived cells can often serve as feeder cells to maintain primate embryonic stem cells in a state capable of producing hematopoietic cells. Cell Biol Int 32:1–7
Ciavarella S, Dammacco F, De Matteo M, Loverro G, Silvestris F (2009) Umbilical cord mesenchymal stem cells: role of regulatory genes in their differentiation to osteoblasts. Stem Cells Dev
Tian X, Fu RY, Chen Y, Yuan LX (2008) Isolation of multipotent mesenchymal stem cells from the tissue of umbilical cord for osteoblasts and adipocytes differentiation. Sichuan Da Xue Xue Bao Yi Xue Ban 39:26–29
Passeri S, Nocchi F, Lamanna R, Lapi S, Miragliotta V, Giannessi E, Abramo F, Stornelli MR, Matarazzo M, Plenteda D, Urciuoli P, Scatena F, Coli A (2009) Isolation and expansion of equine umbilical cord-derived matrix cells (EUCMCs). Cell Biol Int 33:100–105
Honsawek S, Dhitiseith D, Phupong V (2006) Effects of demineralized bone on proliferation and osteogenic differentiation of mesenchymal stem cells from human umbilical cord. J Med Assoc Thai 89(Suppl 3):S189–S195
Acknowledgments
The authors are grateful to Martina Weiss for her support with the production of the figures and to Stefanie Boehm for the critical reading of this work.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Moretti, P. et al. (2009). Mesenchymal Stromal Cells Derived from Human Umbilical Cord Tissues: Primitive Cells with Potential for Clinical and Tissue Engineering Applications. In: Kasper, C., van Griensven, M., Pörtner, R. (eds) Bioreactor Systems for Tissue Engineering II. Advances in Biochemical Engineering / Biotechnology, vol 123. Springer, Berlin, Heidelberg. https://doi.org/10.1007/10_2009_15
Download citation
DOI: https://doi.org/10.1007/10_2009_15
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-16050-9
Online ISBN: 978-3-642-16051-6
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)